TY - JOUR
T1 - Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms
AU - Vijayvergia, Namrata
AU - Dasari, Arvind
N1 - Funding Information:
This work is supported by Cancer Center Support Grant (CCSG) P30 CA006927.
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Ongoing advances in our understanding of neuroendocrine tumor (NET) biology, genetics, and immunology, will continue to expand the availability of targeted therapies, thus improving the outcomes of patients. Well-differentiated neuroendocrine tumors (NETs) are grouped into pancreatic and non-pancreatic NETs (includes GI and thoracic NETs) for treatment considerations (Fig. 1). For panNETs, initial therapy is driven by the need of radiographic response, and targeted agents are typically reserved for second and third line based on the toxicity profile. Treatment options for non-pancreatic NETs are also expanding and while SSAs are the typical first-line option, everolimus and PRRT both remain approved therapies for future lines, and VEGF TKIs are showing promising results in research settings. Sequencing these agents and best time to incorporate peptide receptor radio therapy into the management algorithm remains an unmet need.
AB - Ongoing advances in our understanding of neuroendocrine tumor (NET) biology, genetics, and immunology, will continue to expand the availability of targeted therapies, thus improving the outcomes of patients. Well-differentiated neuroendocrine tumors (NETs) are grouped into pancreatic and non-pancreatic NETs (includes GI and thoracic NETs) for treatment considerations (Fig. 1). For panNETs, initial therapy is driven by the need of radiographic response, and targeted agents are typically reserved for second and third line based on the toxicity profile. Treatment options for non-pancreatic NETs are also expanding and while SSAs are the typical first-line option, everolimus and PRRT both remain approved therapies for future lines, and VEGF TKIs are showing promising results in research settings. Sequencing these agents and best time to incorporate peptide receptor radio therapy into the management algorithm remains an unmet need.
KW - NETs
KW - Neuroendocrine
KW - Recent advances
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85092188580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092188580&partnerID=8YFLogxK
U2 - 10.1007/s11864-020-00794-0
DO - 10.1007/s11864-020-00794-0
M3 - Review article
C2 - 33029680
AN - SCOPUS:85092188580
SN - 1527-2729
VL - 21
JO - Current treatment options in oncology
JF - Current treatment options in oncology
IS - 12
M1 - 96
ER -